Abstract. Two human IgMs (sHIgM12 and sHIgM42) were identified that supported in vitro central nervous system (CNS) neurite extension equal to the potent neurite stimulatory molecule laminin. Both IgMs bound to multiple cell types in unfixed CNS tissue and to the surface of neurons in culture. Both monoclonal antibodies (mAbs) overrode the inhibitory effect of CNS mouse myelin on granule cell neurite extension. Neither mAb bound to the surface of mature oligodendrocytes or strictly colocalized with myelin proteins. Sialidase treatment eliminated the neuronal surface binding of both mAbs, whereas blocking sphingolipid synthesis with Fumonisin B 1 or removing GPI-linked proteins with PIPLC did not. When used as substrates for mixed neuron/glia aggregates, sHIgM12 and sHIgM42 supported robust neurite extension while astrocytes remained in the aggregates. In contrast, laminin supported astrocyte migration and spreading. Human mAbs that support neurite extension are novel factors that may be of use in encouraging axon repair following injury while minimizing glial cell infiltration. Both human mAbs were isolated from individuals with monoclonal gammopathy. Each individual has carried high mAb titers in circulation for years without detriment. sHIgM12 and sHIgM42 are therefore unlikely to be systemically pathogenic.
INTRODUCTION
It is generally accepted that axons of the adult brain and spinal cord do not successfully regenerate following injury due to the synthesis of a glial scar at the lesion site and the presence of a number of inhibitory molecules exposed following the breakdown of myelin (1) (2) (3) (4) (5) (6) . Central nervous system (CNS) axons retain their ability to regenerate when provided with an appropriate environment, such as peripheral nerve graphs, where CNS axons will extend significant distances (7, 8) . Despite such environmental hurdles, histological studies dating to Ramon y Cajal (9) revealed that the adult CNS does have a limited capacity of endogenous repair. Following injury, spinal cord tissue distal to the site of injury maintained aspects of normal histology and axon responsiveness (10, 11) . Intact white matter does not inhibit axon extension to the degree that degenerated white matter does, for when CNS neurons were transplanted beyond the site of injury, axons extended within the white matter (12, 13) . Therefore, a period following injury likely exists when therapeutic interventions to encourage axon growth through the area of damaged myelin and to limit glial scar formation can be beneficial. Therapeutic strategies to enhance axon regeneration fall into 2 general categories-strategies to block endogenous inhibitory factors and strategies to provide a factor or substrate that overrides inhibitors to axon extension.
There is considerable evidence that antibodies (Abs) can modulate CNS repair. Administration of a mAb against an axon growth inhibitory fraction of myelin improved axon regeneration through the lesioned area (2) . It was hypothesized that the mAb partially neutralized in vivo inhibitors to axon extension. Polyclonal Abs synthesized in situ in response to white matter immunization may mimic immune-mediated aspects of an endogenous CNS repair response. In the Theiler's murine encephalomyelitis virus (TMEV)-mediated model of multiple sclerosis (MS), immunization with spinal cord homogenate (SCH) prior to spinal cord demyelination resulted in significantly more remyelination (14) . The direct transfer of sera or purified immunoglobulin (Ig) from SCH-immunized, uninfected mice to non-immunized, TMEV-infected mice promoted the same degree of remyelination as pre-immunization (15, 16) . Analogous immunization of mice with SCH prior to axonal injury resulted in more axon extension through the lesion site than that observed in non-immunized mice (17) . Although it has not been directly proven that Abs are the functional agents in the axon regeneration studies, this is implied by several observations. Within individual mice an elevated titer of Abs directed against myelin correlated with the degree of axon extension, and the SCH anti-sera blocked myelinderived neurite outgrowth inhibition in vitro. Since the SCH anti-sera was thought to promote axon extension by blocking endogenous outgrowth inhibitors, it was surprising to discover that the level of Abs to known CNS inhibitors of axon regrowth (MAG, Nogo, CSPGs) were not elevated over non-immunized mice (18) . Screening for human mAbs that bound to CNS cells. Slices of unfixed cerebellum from 8 week SJL/J mice were incubated with 10 g/ml purified human mAb or undiluted immortalized B-cell clone supernatant followed by appropriate fluorochrome-conjugated F(abЈ) 2 fragments. Two human mAbs bound strongly to a single cerebellar layer, AKJR4 (G), identified the internal granular layer (IGL), whereas sHIgM22 (D) identified the central white matter (WM) of the folia. Additional human mAbs bound to several cerebellar layers. sHIgM12 (A) and sHIgM42 (E) labeled the molecular layer (ML), the IGL and the WM. Double label immunocytochemistry using sHIgM12 (A) and a mAb directed against the mature myelin protein, MOG (B)
Using binding to myelin and oligodendrocytes (OLs) as an initial screen, a number of mouse and human mAbs were identified that promoted remyelination in the TMEV-mediated model of demyelination (19, 20) . Several of the mAbs that promoted remyelination bound to known OL plasma membrane lipids. The ability of a mAb to promote remyelination in vivo correlated with the ability to induce transient Ca 2ϩ influx in OLs in culture (21) . It is reasonable to propose that mAbs that promote remyelination interact in vivo directly with the cells responsible for myelination.
Similarly, if the SCH anti-sera that promoted axon regeneration acted directly upon neurons, then neuronbinding mAbs may encourage axon outgrowth in vivo. Such mAbs would offer new therapeutic strategies to influence recovery from CNS injury. To begin to test this hypothesis, a collection of human sera obtained from individuals with monoclonal gammopathy, a condition characterized by high concentrations of monoclonal serum mAb, was screened for the presence of mAbs that bind to neurons. This report details the identification of 2 human mAbs that bound to the surface of neurons, supported robust neurite extension when presented as substrates, and overrode the neurite extension inhibition of CNS myelin. Human mAbs that support neurite outgrowth are novel molecules that may be useful factors to encourage axon extension following injury.
MATERIALS AND METHODS

Antibodies
Hybridomas A2B5, R24, and HNK-1 were obtained from ATCC (Manassas, VA). A2B5 is a mouse IgM anti-ganglioside (22, 23) . R24 is a mouse IgG anti-GD3 (24) . O4 is a mouse IgM anti-sulfatide (25, 26) . The mouse IgG anti-MOG clone 8-18C5 was obtained from C. Linnington. Mouse anti-Thy-1.1 (clone OX-7) was from BD PharMingen (San Jose, CA). IgG producing hybridomas were grown in serum-free, protein-free medium (Sigma, St. Louis, MO) and purified by ammonium sulfate precipitation, a protein A column and dialysis against PBS. IgM producing hybridomas were grown in 50% serumfree, protein-free medium, 50% RPMI 1640 (Sigma) with 1% FCS (Life Technologies, Grand Island, NY). IgMs were purified by PEG precipitation, water precipitation, and a superose-6 column. Purity and concentrations were determined by SDS-PAGE. Fluorochrome conjugated affinity purified F(abЈ) 2 fragments of goat anti-mouse IgM m chain specific, anti-mouse IgG Fc ␥ fragment specific, anti-human IgM Fc 5 fragment specific, and anti-human IgG Fc ␥ fragment specific are from Jackson ImmunoResearch (West Grove, PA).
Human Abs
Human serum samples obtained from the Mayo Clinic dysproteinemia clinic were selected solely by the presence of an Ig clonal peak of greater than 20 mg/ml. Sera were from 102 patients with a variety of conditions, including Waldenström's macroglobulinemia, multiple myeloma, lymphoma, and MU-GUS. IgM-containing sera were dialyzed against water and separated on a Superose-6 column. IgM fractions were analyzed by SDS-PAGE and pooled. Human IgG-containing sera were diluted 1:20 for testing. Human peripheral B cells from normal adults, adults with rheumatoid arthritis (AKJR), adults with MS and from fetal cord blood (CB) were immortalized using Epstein-Barr virus (ATCC #CRL 1612). Ab-containing supernatants were tested directly.
Cerebellar Slice Immunocytochemistry
SJL mice were obtained from Jackson Labs (Bar Harbor, ME). Holtzman Sprague-Dawley rats were obtained from Harlan (Indianapolis, IN). All animal handling and procedures were done in accordance with the guidelines and approval of the Mayo Clinic and Foundation Institutional Animal Care Committee. Cerebellar slice immunocytochemistry was performed as described (27) . Abs were used at 10 g/ml in HEPES-buffered Earle's balanced salt solution (E/H) or as undiluted supernatant with 1% BSA. A fluorescently conjugated F(abЈ) 2 fragment was used for visualization. Slices were mounted with Vectashield (Vector Labs, Burlingame, CA) and 10 g/ml bisbenzimide for nuclear localization. Images were obtained with an Olympus Provis epifluorescent microscope and a SPOT digital camera (Diagnostic Instruments Inc., Sterling Heights, MI).
Cell Culture
Granule neurons were prepared as previously described, with some modifications (28) . Cells from P6 rat cerebella were suspended in DMEM/F12 with 10% FCS, 6.0 g/l glucose, 0.1 g/ ml penicillin/streptomycin, 2 mM glutamine, and 25 mM KCl (29) and plated onto plastic Petri dishes (BD PharMingen) to allow glial adherence. Non-adherent cells were passed through a 30-m mesh and resuspended in Neurobasal/B27 (1:50), N2 (1:100), glutamine, pen/strep (all from Life Technologies, Carlsbad, CA), 6.0 g/l glucose, and 25 mM KCl. Glial contamination was never more than 2% as determined by immunocytochemistry. Purified OLs were isolated as in (30) immunocytochemistry, cells were seeded at 50,000 cells/cm 2 ; granule cells onto poly-D-lysine-(PDL)-coated coverslips (Fisher Scientific, Chicago, IL); OLs onto poly-L-ornithine-coated coverslips. Immunolabeling was performed on ice. After blocking with 4% BSA E/H, cells were incubated with Abs at 10 g/ ml in 1% BSA in E/H. After washing and fixation with 4% PF, fluorochrome-conjugated F(abЈ) 2 fragments were used for visualization. Aggregates of cerebellar cells were prepared as described (31) . Ten l containing 3.5 ϫ 10 4 cerebellar cells, prior to the removal of glia, were spotted onto the lid of a 96-well dish and the lid inverted to create hanging drops. The resulting mixed aggregates were seeded onto nitrocellulose-treated laminin or mAb-coated wells. After 48 h, aggregates were fixed and stained with Coomassie blue for bright field microscopy. Parallel wells were double immunolabeled with anti-neurofilament 150 kd (Chemicon, Temecula, CA) and anti-GFAP (BD PharMingen) to localize neuronal processes and astrocytes.
Neurite Outgrowth Assay
Nitrocellulose-coated 48-well tissue culture plastic (Costar) was prepared as described (32) . Wells were incubated with mAbs or mouse laminin (Life Technologies) in DMEM/F12 for 16 h at 4ЊC. Plates were washed and filled with DMEM/F12 until cell seeding. Granule cells were seeded at 20,000 cells/ cm 2 in Neurobasal/B27 medium. Cultures were incubated until significant neurite extension was observed on the laminin-coated wells, normally 18 to 20 h. Cultures were fixed and neurites visualized with Coomassie blue stain. Ten to twelve 0.27 mm 2 adjacent frames from at least 2 identical wells were recorded for each substrate in each experiment as bright-field digital images at a magnification of ϫ200. Granule cell attachment was determined using these images. Neurite length was determined using a Drawing Slate II (CalComp, Columbia, MD) and KS 400 graphics software (Kontron Elektronic, GmbH). Neurites were measured only if the end of the neurite could be visualized. Neurites were measured whether or not they contacted another soma or neurite. Five hundred to 800 neurites were measured for each group in at least 3 separate cultures. The frequency distribution of neurite length was determined and displayed using Microsoft Excel and SigmaPlot for Windows (Jandel Scientific Software, San Rafael, CA). Statistical comparisons were done using Kruskal-Wallis 1-way ANOVA on ranks pairwise in SigmaStat (Jandel).
Neurite Extension on Myelin
Assays were done as previously described (17) . Forty-eightwell plates were coated with nitrocellulose (as above) and 25 g/ml PDL. Two g of SJL/J mouse spinal cord myelin, prepared according to (33) , in a 20-l drop was placed in the center of each well and dried. After washing, 100 l of 10 g/ml mAbs or laminin were added and the plates incubated overnight at 4ЊC. Wells were washed 2ϫ with DMEM/F12 and 25,000 granule cells seeded in Neurobasal/B27. After 24 h, cultures were fixed with 4% PF and labeled with anti-neurofilament 150 kd. Images were collected from 3 separate wells at ϫ200 using an Olympus inverted microscope equipped with a SPOT digital camera. Ten to 12 adjacent images were collected beginning 300 m inward from the edge of the myelin spot. The mean length of at least 300 neurites per group was determined using a Drawing Slate II and KS 400 graphics software. Statistical comparisons were done using Kruskal-Wallis 1-way ANOVA.
Enzyme and Inhibitor Treatment
Sialidase from C. perfringens (Worthington Biochemicals Corp, Lakewood, NJ), which cleaves N-acetyl neuraminic acid from a variety of glycoproteins and glycolipids, was added to granule cells at 1 day in culture at a final concentration of 0.1 U/ml for 24 h. Fumonisin B 1 (Sigma), an inhibitor of sphingolipid synthesis, was added to cultures at final concentration of 10 M beginning at 1 day in culture and renewed every other day for 4 days. Phosphatidyl-inositol-specific phospholipase C (Sigma) was added to cultures at a final concentration of 0.05 U/ml for 1 h. Surface immunocytochemistry of unfixed cells was performed as described above.
RESULTS
Human mAbs Bound to the CNS
Human IgMs reactive to the surface of OLs promoted repair of spinal cord lesions in the TMEV-mediated mouse model of MS and in lysolecithin-induced demyelination (20, 34) . We hypothesized that human mAbs that bind to the surface of neurons may be potential neuronal signaling molecules. Sera from 102 humans with a variety of conditions characterized by a monoclonal Ig spike and supernatants from 74 human B cell clones were screened for binding to unfixed slices of mouse and rat cerebellum. Unfixed tissue slices were used because freezing or even light fixation of tissue can compromise the reactivity of Abs that bind to lipids or carbohydrates (27, 35) . Nine human mAbs (all IgMs) of 176 mAbs tested, bound to neuronal layers in slices of cerebellum (Table) .
The binding patterns of several human mAbs to cerebellar slices are presented in Figure 1 . Several mAbs bound to multiple morphologically distinct layers (Fig.  1A , C, E, F). Two human mAbs (AKJR4 and sHIgM22) were specific for 1 cerebellar layer. The B-cell line AKJR4 produced a mAb that bound to the internal granular layer (IGL) (Fig. 1G) . When viewed at high magnification the AKJR4 mAb defined individual granule cell soma (data not shown). sHIgM22 bound to the central white matter of the folia (WM) and myelinated tracts in the IGL (Fig. 1D) , similar to that observed with anti-MOG mAb (Fig. 1B) . sHIgM14 labeled Purkinje cell soma at the slice surface, radial strands within the molecular layer (ML), and the WM (Fig. 1C) . sHIgM46 bound to the WM and the Purkinje cell layer (Fig. 1F ). sHIgM12 and sHIgM42 (Fig. 1A, E) , bound to multiple cerebellar layers. sHIgM12 clearly labels the WM and ML in Figure 1A and at higher magnification Purkinje and granule cells (data not shown). A nearly confluent label at the cut surface of the tissue slice over the ML suggested that sHIgM12 or sHIgM42 may bind to an extracellular matrix molecule. The patterns in which human mAbs bound to the cerebellum were similar to those observed using anti-glycolipid (27) and anti-ganglioside mAbs (36) . sHIgM39 is an example of a non-reactive human IgM (Fig. 1H) . Control slices (i.e. omission of the primary mAb or of both primary and secondary Abs) were always incubated in parallel to determine nonspecific background and autofluorescence. Both control conditions presented only faint nonspecific labeling of the IGL (not shown
Human mAbs Supported Neurite Extension Equal to that Supported by Laminin
Human mAbs that bound to neurons in cerebellar slices were tested as substrates for cerebellar granule cell attachment and neurite extension (Table) . Laminin was used as a positive control throughout the studies. Neurite extension assays were performed at least 3 times, utilizing triplicate samples. At 24 h following cell seeding, only sHIgM12 and sHIgM42 supported neurite extension and cell attachment similar to that supported by laminin ( Fig. 2A-C) . Granule cells seeded onto BSA-coated wells distributed evenly and elaborated short neurites (not shown, similar to Fig. 1F ). When seeded onto sHIgM22 (Fig. 2E) , which bound to WM and OLs, granule cells settled in clumps and extended short neurites. Granule cells seeded onto AKJR4, which bound intensely to the IGL in cerebellar slices, settled in clumps and adhered weakly (data not shown).
Two mouse anti-gangliosides, R24 and A2B5, were tested as substrates for neurite extension. Both supported a significant population of neurites (Fig. 2D, G) . ANOVA pairwise comparison on ranks indicated no difference between the neurite population supported by 10 g/ml of A2B5, laminin, sHIgM12, or sHIgM42 to a significance of p Ͻ 0.05, while the neurite population supported by R24 was different. R24 induced more neurites per neuron than any other Ab tested. Laminin, sHIgM12, sHIgM42, and A2B5 supported 2 long dominant neurites per cell, whereas granule cells seeded onto R24 often elaborated 5 or more processes per cell (data not shown). The population of neurites supported by all other human mAbs Table) . Quantifying neurite extension supported by mAbs (G). The distribution frequency of granule cell neurite lengths 24 h post-seeding when cultured on substrate mAbs. Granule cells seeded on laminin, sHIgM12, sHIgM42, and A2B5 extended a large population of neurites longer than 300 m within 24 h. Granule cells seeded on other human mAbs or BSA did not extend a population of neurites longer than 300 m (Table) . ANOVA of the total neurite length populations indicated that the neurites extended on laminin, sHIgM12, sHIgM42 and A2B5 were not different to a significance of p Ͻ 0.05. Figure  2G represents 1 of 4 independent neurite extension assays. In all trials, sHIgM12, sHIgM42, A2B5, and laminin supported statistically similar populations of neurites. Scale bar: 100 m.
was compared to laminin, sHIgM12, and sHIgM42-none reached a significance of p Ͻ 0.05. Substantial neurite extension was supported in wells coated with sHIgM12, sHIgM42 or laminin at concentrations down to 1 g/ml. High concentrations (250 g/ml) of sHIgM12 or sHIgM42, used as substrates or in solution, did not induce longer neurites, alter cell attachment, or otherwise appear toxic.
Although sHIgM12, sHIgM42, and laminin supported equivalent neurite extension from purified granule cells, when used as substrates for aggregates of cerebellar cells, significant differences in the support of cell migration and spreading were observed. When aggregates were seeded onto laminin, widespread GFAP ϩ astrocytic spreading accompanied neurofilament ϩ neurite outgrowth and neuron soma migration over 48 h (Fig. 3A , Coomassie blue stain shown). In contrast, when aggregates of cerebellar cells were seeded onto sHIgM12 or sHIgM42, only robust neurofilament ϩ neurite extension was observed. GFAP ϩ astrocytes remained within the cell aggregates (Fig. 3B , C). sHIgM12 and sHIgM42 did not bind to the surface of astrocytes.
Human mAbs Bound to Dissociated Neurons In Vitro
When human mAbs were further screened for binding to the surface of granule cells during the first 24 h in culture, only sHIgM12 and sHIgM42 bound (Fig. 4A, B) . At the same time in culture R24 and A2B5 also bound to the surface of granule cells (Fig. 3C, D) . AKJR4 did not bind to the surface of granule neurons in culture at any time tested (Fig. 4E) Epitopes Bound by sHIgM12 and sHIgM42 were Sensitive to Sialidase, but not to Treatment with FB 1 or PIPLC
To determine the nature of the epitopes bound by sHIgM12 and sHIgM42, granule cells were treated with fumonisin B 1 (FB 1 ) to downregulate sphingolipid expression, PIPLC to cleave GPI-linked molecules, or sialidase to cleave sialic acid. FB 1 inhibits sphingolipid synthesis by blocking the acylation of sphingoid long chain bases. Treatment of hippocampal neurons with 50 M FB 1 for 3 days reduced sphingolipid synthesis to 10% of normal levels and eliminated the binding of anti-ganglioside Abs (37) . Treatment of granule cells with as little as 10 M FB 1 for 5 days eliminated surface GD3 (Fig. 5C, D) , but did not effect the binding of sHIgM12 or sHIgM42 (Fig.  5A, B) . When granule cells were treated with PIPLC at a concentration of 0.05 U/ml for 1 h, the binding of antiThy-1, a GPI-linked neuronal protein (38) , was eliminated ( Fig. 5G, H) , but did not alter the binding of sHIgM12 or sHIgM42 (Fig. 5E, F) .
In contrast, treatment of granule cells for 6 h with as little as 0.1 U/ml sialidase completely eliminated the binding of sHIgM12 and sHIgM42 (Fig. 5I, J) and greatly reduced the binding of A2B5 (Fig. 4K, L) . As a control for non-specific protease activity the binding of HNK-1 (39) to granule cells was unaltered by sialidase treatment (data not shown). We concluded that the binding of sHIgM12 and sHIgM42 to the surface of granule cells was carbohydrate dependent. sHIgM12 and sHIgM42 did not Bind to Mature Oligodendrocytes or Colocalize with Myelin Proteins sHIgM12 and sHIgM42 bound to layers of the adult cerebellum that contained neurons, OLs, and myelin. To determine the OL component of this tissue label, OLs maintained for 2 weeks in vitro were surface immunolabeled. Neither sHIgM12 nor sHIgM42 bound to the surface of morphologically complex sulfatide-positive OLs (Fig. 6A-D) . In contrast, sHIgM22 bound strongly to sulfatide-positive OLs (Fig. 6E, F) . sHIgM22 is a human mAb that promoted remyelination and colocalized with anti-MOG in cerebellar slices (40) . In contrast, sHIgM12 and sHIgM42 did not strictly colocalize with anti-MOG immunostaining in cerebellar slices (Fig. 1A, B, E) . 
sHIgM12 and SHIgM42 Overrode the Neurite Extension Inhibition of CNS Myelin
Since laminin has been shown to override the neurite extension inhibition of CNS myelin (41) , sHIgM12 and sHIgM42 were tested for the ability to allow neurite extension on myelin (Fig. 7) . Two g spots of dried mouse spinal cord myelin were incubated with mAbs at 10 g/ ml and then seeded with granule cells. At least 300 neurofilament ϩ neurites elaborated on the myelin spots were measured for each group. Neurites on untreated myelin averaged 13 Ϯ 2 m while neurites on PDL averaged 31 Ϯ 2 m. In contrast, neurites on myelin treated with laminin, sHIgM12 or sHIgM42 were significantly longer (29 Ϯ 8, 32 Ϯ 3, and 29 Ϯ 2 m, respectively). On myelin treated with the control mAb sHIgM39, neurite length was 17 Ϯ 1 m. Statistical comparison of neurite length on untreated myelin was different than the neurite length on myelin pre-treated with laminin, sHIgM12, or sHIgM42 (p ϭ Ͻ0.001).
DISCUSSION
We have identified 2 human IgMs (sHIgM12 and sHIgM42) that when presented as substrates supported neurite extension from CNS neurons equal to that induced by laminin. Screening for biologically active human mAbs was performed in an antigen independent sHIgM42 (B) were maintained following treatment of 50 M FB 1 , whereas ganglioside epitopes bound by R24 were present on untreated cells (C), but lost in the presence of FB 1 (D). Treatment with FB 1 was for 5 days beginning 12 h after cell seeding. Surface epitopes bound by sHIgM12 (E) and sHIgM42 (F) were also maintained following treatment with PIPLC, whereas the GPI-linked protein Thy-1, present on untreated cells (G), was lost following PIPLC cleavage. Cultures were treated with 0.05 U/ml PIPLC for 1 h prior to immunocytochemistry. In contrast, surface epitopes bound by sHIgM12 (I) and sHIgM42 (J) were lost following treatment with sialidase. Epitopes bound by A2B5 (K) were ← also lost following sialidase digestion (L). Granule cells at 3 days in culture were treated with sialidase for 12 h prior to immunocytochemistry. Scale bar: 100 m.
manner. Any human mAb that bound to neurons in an unfixed slice of cerebellum was tested as a substrate for neurite outgrowth. The binding pattern of sHIgM12 and sHIgM42 to layers of the cerebellum and to the surface of neurons, combined with epitope sensitivity to extraction, enzymatic cleavage, and metabolic inhibitors suggested that the mAb binding sites are carbohydrates associated with lipids. In support of this conclusion, 2 mouse anti-ganglioside mAbs (A2B5 and R24), chosen because each bound to the surface of neurons, also supported neurite extension.
Both sHIgM12 and sHIgM42 also reduced the inhibitory effects of mouse CNS myelin on neurite extension, a characteristic shared by laminin (41) . However, an outgrowth assay using cerebellar neuron/glia aggregates demonstrated differences between the mAbs and laminin. sHIgM12 and sHIgM42 did not support astrocyte spreading or migration from the aggregates, whereas laminin did. In aggregates cells have additional choices between suitable substrates (31) . Granule cells prefer to extend short neurites toward other granule cells unless provided with a more attractive substrate. The aggregate culture studies suggest that sHIgM12 and sHIgM42, if provided as substrates in vivo, may drive axon outgrowth and control astrocyte migration, minimizing glial scar formation. When assayed for binding to dried myelin by ELISA, sHIgM12 and sHIgM42 bound very weakly compared to O4, anti-MOG, and sHIgM22 (unpublished data). Further studies will determine whether sHIgM12 and sHIgM42 bind to myelin directly and cover inhibitory epitopes or act similarly to laminin, offering an adhesive substrate that effectively competes with inhibitory epitopes. sHIgM12 and sHIgM42 are fundamentally different from the IN-1 and anti-Nogo mAbs that allow axon outgrowth in several models of CNS injury, presumably by blocking inhibitory molecules (2, 42) . IN-1 bound to mature OLs and strictly colocalized in tissue sections with mAbs against MOG (43) . In contrast, sHIgM12 and sHIgM42 did not bind to mature OLs or colocalize with mature myelin antigens. SCH antisera that promoted remyelination (15) and axon regeneration (17) bound to myelin and myelin proteins, but not to known myelin inhibitors (18) . The anti-neuronal character of SCH antisera remains largely unexplored. However, SCH antisera with demonstrated ability to promote remyelination bound strongly to neuronal layers of the cerebellum (unpublished data). Following optic nerve lesion, retinal ganglion axon growth occurred within areas permeable to Abs (18) , supporting the concept that axons can utilize Abs as adhesive substrates or signaling molecules in vivo. Perhaps the anti-myelin Abs of SCH antisera participate in the promotion of remyelination, whereas antineuronal Abs of SCH antisera participate in promoting axon outgrowth. At least in vitro, sHIgM12, sHIgM42, laminin, and SCH antisera all provide sufficient incentive to allow neurites to ignore inhibitory myelin substrate molecules.
We hypothesize that sHIgM12 and sHIgM42 bind to neuronal gangliosides. Gangliosides can serve as receptors for ligand and Ab-mediated neuronal signaling (44) . Anti-GM1 mAbs suppress neurite outgrowth (45) . The axon outgrowth inhibition of MAG is mediated through GD1a and GT1b. Removal of the terminal sialic acid residues from neurons eliminated the inhibitory effect of MAG (46) GD1 mimics the effect of MAG (47, 48) . Abs to GD3 or the GPI-linked protein, TAG-1, activated Lyn and induced similar alterations in protein-tyrosine phosphorylation. Removal of surface carbohydrates reduced the level of membrane GD3 and eliminated Ab-mediated signaling (49, 50) . Anti-ganglioside Abs, especially pentameric IgMs, likely act as ligands by clustering plasma membrane lipid rafts containing signal transduction complexes.
Laminin would appear to be an ideal candidate molecule to encourage axon re-growth if delivered to the site of CNS injury. Laminin, normally absent in the adult CNS, is upregulated following injury (51) and is likely an aspect of endogenous CNS repair (52) . The effectiveness of laminin for nerve regeneration has been demonstrated (53) . However, laminin-1 is a large molecule, difficult to synthesize and potentially tumorigenic (54) . Therefore, smaller functional domains of laminin or molecules that mimic laminin have been sought. The ␥1 chain of laminin or a tripeptide portion retained the ability to promote neurite extension and allowed axon extension in the presence of CNS myelin (55, 56) . Both molecules supported neurite extension in vitro within a narrow concentration range and appear to be toxic to neurons at higher concentrations. The accumulation of ␥1 chain in the brain was associated with Alzheimer disease and Down syndrome (57) . If used in vivo, controlling the local concentration of these molecules will be critical. Anti-Thy-1 Abs induced neurite extension when used as a substrate (58) . However, anti-Thy-1 Abs were systemically pathogenic to the nephritic glomeruli and vascular endothelium and are routinely used to initiate a model of nephritis (59, 60) . sHIgM12 or sHIgM42 have in a real sense been prescreened for in vivo toxicity in the patients that synthesize the molecules. Despite having carried high levels of these mAbs for many years neither individual presents with Ab-mediated dysfunction. sHIgM12 and sHIgM42 were injected into chronically TMEV-infected mice, where the blood brain barrier is open, with no deleterious effects. Neurons maintained in culture for weeks in the presence of 250 g/ml of sHIgM12 or sHIgM42 were unaffected.
Abs synthesized following CNS injury may participate in repair, as modeled by the SCH pre-immunization studies and equivalent repair can be obtained by the exogenous addition of mAbs. Human mAbs have a number of advantages as therapeutic molecules. They are likely to be minimally antigenic when administered systemically-Abs are normally present in the circulation-and have a limited life span in the recipient. In contrast, administering an antigen to induce an individual to synthesize their own reparative Abs may result in unpredictable immune reactions across the population. Recombinant human mAbs can be synthesized free of infectious agents and easily molecularly altered (40) . When administered systemically, mAbs that promoted remyelination localized to areas of demyelination (61) and SCH antisera localized to lesioned areas of the optic nerve (18) . Thus, therapeutic human mAbs administered systemically may localize to sites of injury. Human mAbs may be one component of a combinatorial reparative strategy (utilizing cell transplantation, neurotrophic factors, or degradative enzymes) delivered to the lesion site. mAbs can be incorporated into biodegradable polymer matrices that when implanted can provide a local supply (62) or used to line guidance channels of polymer implants, which may assist in promoting directional axonal growth and inhibit glial infiltration. Human mAb-based therapeutics may offer a specificity of binding and, potentially, of action not possible with other reagents. Future studies will determine whether human mAbs that promote neurite extension have utility in CNS repair.
